Caroline Humer

health & pharma, for Reuters

[pharmalot @pharmalot]

Pharmalot.. Pharmalittle.. Good Morning: Illumina will divest Grail after court finds deal was anti-competitive; FDA found problems at Moderna facility & More news.. https://t.co/Tlkg9XE6p2 #pharma #biotech #FDA #hemophilia #weightloss #obesity #raredisease $NVO $ILMN $GPCR $CKPT

[Reuters @Reuters]

Exclusive: US FDA finds control lapses at Moderna manufacturing plant https://t.co/qZQDBEQevw

[Reuters Health @Reuters_Health]

Some patients with type 2 diabetes say they are having more difficulty getting reimbursed for drugs like Ozempic as U.S. insurers implement restrictions designed to deter doctors from prescribing the medication for weight loss. https://t.co/B7HY3lxNE7 https://t.co/B7HY3lxNE7

[Reuters Health @Reuters_Health]

Researchers return to Alzheimer's vaccines, buoyed by recent drug success https://t.co/xX5qBMEtgr https://t.co/xX5qBMEtgr

[Reuters Health @Reuters_Health]

The U.S. government on Monday will start taking orders for another round of free COVID-19 tests for delivery across the country, a Department of Health and Human Services (HHS) spokesperson said. https://t.co/iEKdx7ExA8 https://t.co/iEKdx7ExA8

[Reuters @Reuters]

Down syndrome families' fight for access to Alzheimer’s trials, treatments https://t.co/c3wJvaPbyT

[Reuters Health @Reuters_Health]

Two U.S. senators are demanding that the nation's three largest insulin makers, Novo Nordisk , Eli Lilly , and Sanofi , provide details by Sept. 15 of their programs to help Americans get their insulin for $35 a month or less. https://t.co/sGgcmc3Cnn

[Reuters Health @Reuters_Health]

Reimbursement of Novo Nordisk's weight-loss drug Wegovy for the 900,000 people in Denmark who are considered obese would cost the Danish state as much as $4 billion each year, the country's health ministry said on Monday. https://t.co/i7Q5zmFfvU

[Reuters @Reuters]

Once the world's priciest drug at over $2 million, Zolgensma was launched as a possible ‘cure’ for spinal muscular atrophy – a rare disorder which is the leading genetic cause of death in infancy globally. Now, patient outcomes paint a nuanced picture https://t.co/NfU8uFLW6h

[Reuters Health @Reuters_Health]

Focus: US psychiatrists prescribe Wegovy to battle medication-induced weight gain https://t.co/O8QcQhW4vQ

[Reuters Health @Reuters_Health]

Insight: Promising new Alzheimer's drugs may benefit whites more than Blacks https://t.co/f1g72bkuDM

[Reuters Health @Reuters_Health]

Alzheimer's disease experts are revamping the way doctors diagnose patients with the progressive brain disorder - the most common type of dementia - by devising a seven-point rating scale based on cognitive and biological changes in the patient. https://t.co/R7QsZZwwOC

[Reuters Health @Reuters_Health]

Exclusive: Most patients using weight-loss drugs like Wegovy stop within a year, data show https://t.co/wYkvBUmftG

[Reuters Health @Reuters_Health]

Uninsured US patients pay up to $330 for Eli Lilly’s $25 insulin, Senator Warren says https://t.co/HXTVvVMHpb

[Reuters Health @Reuters_Health]

The imminent move to label aspartame as a possible carcinogen comes after years of advocacy from a leading consumer group in the United States and a handful of cancer scientists hoping to settle a decades-long debate over the sweetener's safety. https://t.co/RgxZ791Ubg

[Reuters Health @Reuters_Health]

Cigna Group's Express Scripts pharmacy benefits unit will add three biosimilar versions of AbbVie's blockbuster arthritis treatment Humira to its list of preferred drugs, the company said on Monday. https://t.co/R0ZyDeTbWT

[Reuters Health @Reuters_Health]

Novo Nordisk will start selling its hugely popular obesity drug Wegovy in Germany this month, its third European market, but only people who pay from their own pocket or have certain private health insurance plans will be able to get it. https://t.co/QVLKA3To82

[Reuters Health @Reuters_Health]

The European Medicines Agency is looking into Novo Nordisk's weight-loss drugs Saxenda and Ozempic after "several reports of suicidal risks" were referred to the watchdog, Bloomberg News reported on Monday. https://t.co/SqxRcwLlNg

[Matthew Herper @matthewherper]

Fantastic story by ⁦@NatalieGrover⁩.

We could be about to see two very divergent approaches to dealing with Alzheimer’s. It’s a fascinating and also disheartening situation. Because one continent will be wrong. https://t.co/TuKYH2B4l3